Zhang Tingjian, Lv Yunying, Lei Yu, Liu Dan, Feng Yao, Zhao Jiaxing, Chen Shaolei, Meng Fanhao, Wang Shaojie
Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe District, Shenyang 110016, China; School of Pharmacy, China Medical University, 77 Puhe Road, North New Area, Shenyang 110122, China.
Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe District, Shenyang 110016, China.
Eur J Med Chem. 2018 Feb 25;146:668-677. doi: 10.1016/j.ejmech.2018.01.060. Epub 2018 Jan 31.
In our previous study, we reported a series of 1-hydroxy-2-phenyl-1H-imidazole-5-carboxylic acid derivatives that presented excellent in vitro xanthine oxidase inhibitory potency. As a continuation study, a series of 1-hydroxy-2-phenyl-1H-imidazole derivatives containing a pyridine moiety (4a-g and 5a-g) at the 4-position was designed and synthesized. Evaluation of in vitro xanthine oxidase inhibition demonstrated that the 4a-g series was more potent than the 5a-g series. Compound 4f was the most promising derivative in the series with an IC value of 0.64 μM. A Lineweaver-Burk plot revealed that compound 4f acted as a mixed-type xanthine oxidase inhibitor. An iso-pentyloxy group at the 4'-position improved the inhibitory potency. More interestingly, structure-activity relationship analysis indicated that the pyridine para-N atom played a crucial role in the inhibition. Molecular modeling provided a reasonable explanation for the structure-activity relationships observed in this study. In addition, a three dimensional quantitative structure-activity relationships model which possessed reasonable statistics (q = 0.885 and r = 0.993) was conducted to further understand the structural basis of these compounds as xanthine oxidase inhibitors. These compounds, especially compound 4f, have good potential for further investigations.
在我们之前的研究中,我们报道了一系列1-羟基-2-苯基-1H-咪唑-5-羧酸衍生物,它们在体外表现出优异的黄嘌呤氧化酶抑制活性。作为一项后续研究,我们设计并合成了一系列在4-位含有吡啶部分(4a-g和5a-g)的1-羟基-2-苯基-1H-咪唑衍生物。体外黄嘌呤氧化酶抑制活性评估表明,4a-g系列比5a-g系列更具活性。化合物4f是该系列中最有前景的衍生物,其IC值为0.64 μM。Lineweaver-Burk图表明化合物4f作为混合型黄嘌呤氧化酶抑制剂起作用。4'-位的异戊氧基提高了抑制活性。更有趣的是,构效关系分析表明吡啶对位-N原子在抑制中起关键作用。分子模拟为该研究中观察到的构效关系提供了合理的解释。此外,还构建了一个具有合理统计学意义(q = 0.885和r = 0.993)的三维定量构效关系模型,以进一步了解这些化合物作为黄嘌呤氧化酶抑制剂的结构基础。这些化合物,尤其是化合物4f具有进一步研究的良好潜力。